Auckland envelope manufacturer Candida has been saved from closure. Private equity firm Muri Capital acquired the business in November 2026, securing its future and manufacturing roles.
The firm was finalizing plans to close its local operations. Candida recently announced it is leaving New Zealand.
As a result, Candida is considering a proposal to wind up the New Zealand manufacturing branch with effect from or about November. This proposal affects our New Zealand company, not our Australian one,
Candida representative Goubitz stated, as reported by the Nzherald.
Muri Capital initiated contact with Candida following the closure announcement. The firm also owns the print and manufacturing company Touchprint.
Muri Capital director Guy Phillips described the ensuing discussions as going extremely well.
Production will continue without interruption. The transition is set for November 30, 2026.
We’re here to fill every order, with capacity to meet the needs of customers – especially with the Christmas season approaching,
Phillips said.
Muri Capital plans to operate the brand independently. Some equipment had already been shipped to Australia before this deal.
Negotiations are underway to bring back employees caught in the initial redundancy round. Phillips expects a significant proportion
of the original workforce to return.
Returning staff will receive pay equal to or higher than their previous rates. The firm is honoring original start dates for those on permanent contracts.
Phillips pointed to the specialized expertise of the long-term team. He explained the motivation for the purchase: When you have such good envelopes being manufactured in our own country, we had to get in behind the team and the product.
